Methotrexate-related beliefs, fears, and use among patients with rheumatoid arthritis: a coss-sectional survey
Rheumatology · 09.07.2026 · 64 (4) · 280-286
DOI: 10.5114/reum/218395 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology, online erschienen am 09.07.2026. Verfasst von L'heri Hind und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology B, Ayachi Hospital, Ibn Sina Hospital Center, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
The study aimed to assess the beliefs and fears of Moroccan patients with rheumatoid arthritis (RA) regarding methotrexate (MTX) and to identify factors associated with the total score on the Beliefs about Medicines Questionnaire-Specific (BMQ). Material and methods A single-center cross-sectional study was conducted in patients being treated for RA with MTX. Beliefs about treatment were assessed using the BMQ. Specific fears related to MTX were collected using a structured questionnaire developed for the study. Factors associated with the total BMQ score were explored using univariate and then multivariate linear regression.
Results
One hundred and two patients were included (age: 53.1 ±12.5 years; 90.2% women). The mean BMQ-Concerns score was 15.9 ±6.37. The main concerns were related to potential long-term adverse effects (58.8%), particularly gastrointestinal (65.7%) and hepatic (62.7%) toxicity. A moderate or high level of fear was reported by 53.9% of patients. The mean BMQ-Necessity score was 15.0 ±5.04; 55% felt that their current health depended on MTX, and 51% perceived an overall benefit from the treatment. The median BMQ total score was 1 (from –3 to 4). In multivariate analysis, longer disease duration (β = –0.12; 95% CI: –0.23 to –0.02) and use of the internet as a source of information (β = –2.66; 95% CI: –5.06 to –0.27) were independently associated with the total score.
Conclusions
Moroccan patients with RA generally consider MTX to be necessary but express significant concerns about its toxicity. Disease duration and use of the internet significantly influence these perceptions, highlighting the need for therapeutic education interventions and reliable digital information sources.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology B, Ayachi Hospital, Ibn Sina Hospital Center, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.
- Exercise Physiology and Autonomous Nervous System Team, Physiology Laboratory, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.
- Laboratory of Biostatistics, Clinical and Epidemiological Research, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.
- International University of Rabat (UIR), College of Health Sciences, Research Center of Health Sciences (CreSS), Rabat, Morocco.
ORCID-Profile: L'heri Hind, Rkain Hanan, Tahiri Latifa, Kronbi Fatine, Abouqal Redouane, Hajjaj-Hassouni Najia, Allali Fadoua
Zitieren
APA
Hind, L., Hanan, R., Sara, F., Latifa, T., Fatine, K., Redouane, A., Najia, H. H., & Fadoua, A. (2026). Methotrexate-related beliefs, fears, and use among patients with rheumatoid arthritis: a coss-sectional survey. Rheumatology, 64(4), 280-286. https://doi.org/10.5114/reum/218395
Vancouver
Hind L, Hanan R, Sara F, Latifa T, Fatine K, Redouane A, et al. Methotrexate-related beliefs, fears, and use among patients with rheumatoid arthritis: a coss-sectional survey. Rheumatology. 2026;64(4):280-286. doi:10.5114/reum/218395
BibTeX
@article{Hind2026,
author = {Hind, L'heri and Hanan, Rkain and Sara, Farih and Latifa, Tahiri and Fatine, Kronbi and Redouane, Abouqal and Najia, Hajjaj-Hassouni and Fadoua, Allali},
title = {Methotrexate-related beliefs, fears, and use among patients with rheumatoid arthritis: a coss-sectional survey},
journal = {Rheumatology},
year = {2026},
volume = {64},
number = {4},
pages = {280--286},
doi = {10.5114/reum/218395}
}
EUVIMED